FDA Calendar for ArQule, Inc. (ARQL)

| Register (free)
ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company’s product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).


Drug Pipeline

Drug NameType Of DrugFDA StatusDrug Phase
This company currently does not have any drugs. If you would like to create one please click here.


Events

No future events listed at this time, please check back later.

Add New Event

In order to write a comment you must first login.

Login or Register (for free!)

Add Event

ARQL

$8.14
0.13 +1.62%
2/3/2012 4:00:00 PM

Sponsors

Other Links